Monte Rosa Therapeutics, Inc. GLUE
$17.87
▲ +6.64% 24H
About
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs), a class of small molecule drugs that harness the body's natural protein destruction mechanisms to selectively eliminate therapeutically relevant proteins. The company employs its proprietary Qu…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees187
TickerGLUE
Statistics
Market Cap$1.51B
Revenue (TTM)$123.7M
Net Income-$38.6M
Net Margin-31.2%
EPS—
P/E49.22
P/S32.49
P/B2.67
EV/EBITDA-5.49
ROE-32.6%
Dividend Yield—
Price$17.87
Data: Twelve Data · Revenue = mcap / P/S